SCHEMBL6031468

SCHEMBL6031468

CCCCCCCCOC(=O)Nc1scc(C(CCCC)CCCCC)c1C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.35
TSHR P16473 5/20 0.35
MAPK1 P28482 3/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
EPHX1 P07099 1/20 0.35
CSNK2A2 P19784 2/20 0.34
CSNK2A1 P68400 2/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MMP1 P03956 1/20 0.34
MMP9 P14780 1/20 0.34
MMP12 P39900 1/20 0.34
CASP1 P29466 1/20 0.34
HPGD P15428 1/20 0.34
EPHX2 P34913 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030466 0.87 KDM4E (0.41) L3MBTL1ALDH1A1
SCHEMBL6031361 0.86 CSNK2A2 (0.41) L3MBTL1TSHRMAPK1ALDH1A1MAPT
SCHEMBL6029667 0.82 ALDH1A1 (0.40) L3MBTL1TSHRMAPK1ALDH1A1MAPT
SCHEMBL6030200 0.78 GRM6 (0.38) MAPK1ALDH1A1MAPTHSD17B10SMN1; SMN2
SCHEMBL6030253 0.78 KDM4E (0.42) L3MBTL1ALDH1A1MAPT
SCHEMBL6031467 0.76 PRSS1 (0.42) L3MBTL1TSHRMAPK1ALDH1A1EPHX1
SCHEMBL6029664 0.76 PRSS1 (0.42) L3MBTL1TSHRMAPK1ALDH1A1EPHX1
SCHEMBL6030720 0.72 PKM (0.43) TSHRMAPK1ALDH1A1MAPTHSD17B10
SCHEMBL6030380 0.72 PKM (0.43) TSHRMAPK1ALDH1A1MAPTHSD17B10
SCHEMBL6030376 0.72 PKM (0.52) TSHRMAPK1ALDH1A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL L3MBTL1 1266/4885TSHR 212/4885MAPK1 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.